Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan

Summary

For hemodialysis subjects not receiving ESAs with anemia associated with chronic kidney disease, evaluate Hb correction and maintenance effect and safety of MT-6548.

Timeline

Start

2018-03-05

Primary completion

2018-12-03

Completion

2018-12-17

Publications

• Results Nangaku M, Kondo K, Takabe S, Ueta K, Tandai T, Kawaguchi Y, Komatsu Y. A phase 3, open-label, single-arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis-stimulating agents. Ther Apher Dial. 2022 Feb;26(1):45-54. doi: 10.1111/1744-9987.13699. Epub 2021 Jun 28.

Drugs

Indications